Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Residual CFTR function in cystic fibrosis was associated with better glucose tolerance and insulin secretion, with CFTR ...

A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...

Following a low-carb diet may potentially help patients manage disease more effectively and reduce medication use. Study: Effects of a Carbohydrate-Restricted Diet on β-Cell Response in Adults With ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A restricted ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

Little is known about the impacts of therapy on adolescent patients with T2DM. In a recent study, adolescents with newly diagnosed T2DM had profound impairment of beta-cell function, but treatment ...

People with type 2 diabetes can benefit from seriously cutting down on carbs even when they don’t lose excess weight, a new study says. A low-carb diet can improve the body’s ability to regulate blood ...

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...